(54) Methods of Treating Anxiety and Mood Disorders with Oleamide

Arato M. Banki CM, Bissette G, Nemeroff CB, Elevated CSF CRH in suicide victims. Biological Psychiatry 1989;25:355—359. Baker DG, West SA, Nicholson WE, Ekhator NN, KasckoW JW, Hill KK, Bruce AB, Orth DN, Geracioti TD Jr. Serial CSF corticotropin—releasing hormone levels and adrenocor tical activity in combat veterans With post—traumatic stress disorder. Am J Psychiatry 1999;156:585—588. Banki CM, Bissette G, Arato M, O’Connor L, Nemeroff CB. Cerebrospinal ?uid corticotropin releasing factor—like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144:873—877. Basile AS, Hanus L, Mendelson WB. Characterization of the hypnotic properties of oleamide. Neuroreport 1999;10:947—951. Brady LS, Whit?eld HJ Jr., Fox RJ, Gold PW, Herkenham M. Long—term antidepressant administration alters corti cotropin—releasing hormone, tyrosine hydroxylase, and min eralocorticoid receptor gene expression in rat brain. Thera peutic implications. J Clin Invest 1991;87:831—837. Brady LS, Gold PW, Herkenham M, Lynn AB, Whit?eld HJ Jr. The antidepressants ?uoxetine, idazoxan and phenelzine alter corticotropin—releasing hormone and tyrosine hydroxy lase mRNA levels in rat brain: therapeutic implications. Brain Res 1992;527:117—125. Brady LS, Lynn AB, GloWa JR, Le DQ, Herkenham M. Repeated electroconvulsive shock produces long—lasting increases in messenger RNA expression of corticotropin—re leasing hormone and tyrosine hydroxylase in rat brain. Therapeutic implications. J Clin Invest 1994;94:1263—1268. Casper RC, Kocsis J, Dysken M, Stokes P, Croughan J, Maas J. Cortisol measures in primary major depressive disorder With hypersomnia or appetite increase. J Affect Disord 1988;15:131—140. Cheer JF, Cadogan A—K, Marsden CA, Fone KCF, Kendall DA. Modi?cation of 5—HT2 receptor mediated behavior in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacol 1999;38:533—541. Cravatt BF, Prospero—Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Chemical character ization of a family of brain lipids that induce sleep. Science 1995;268:1506—1509. Cravatt BF. Giang DK, May?eld SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty—acid amides. Nature 1996;384:83—87. Geracioti TD Jr, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT. Serial cerebrospinal ?uid corticotropin—releas ing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992;74:1325—1330. Geracioti TD Jr, Loosen PT, Orth DN. LoW cerebrospinal ?uid corticotropin—releasing hormone concentrations in eucortisolemic depression. Biological Psychiatry 1997;42:166—174. Gold PW, GoodWin FK, Chrousos GP. Clinical biochemical manifestations of depression: Relation to the neurobiology of stress (part II of parts). N Engl. Med 1988;319:413—420. Huidobro—Toro JP, Harris RA. Brain lipids that induce sleep are novel modulators of 5—hydroxytryptaine receptors. Proc Natl Acad Sci USA 1996;93:8078—8082. KasckoW JW, Regmi Gill PS, Parkes DG, Geracioti TD. Regulation of corticotropin—releasing factor (CRF) messen ger RNA and CRF peptide in the amygdala: studies in primary amygdalar cultures Endocrinology 1997;138:4774—4792. Lerner RA, Siuzdak G, Prospero—Garcia O, Henriksen SJ, Boger DL, Cravatt BF. Proc Natl Acad Sci USA 1994;91:9505—9508. Lister RG. The use of a plus maze to measure anxiety in the mouse. Psychopharmacology 92: 180—185, 1987. Mulchahey JJ, Regmi A. Sheriff S. Balasubramanian A, KasckoW JW. Coordinate and divergent regulation of corti cotropin—releasing factor (CRF) and CRF—binding protein expression in an immortalized amygdalar neuronal cell line. Endocrinology 1999;140: 251—259. Nemeroff, C.B., Widerlov E, Bissette G, et al., Elevated concentrations of CSF corticotropin—releasing factor—like immunoreactivity in depressed patients. Science 1984;226:1342—1344. Sachar EJ. Corticosteriods in depressive illness: II. A lon gitudinal psychoendocrine study. Arch Gen Psychiatry 1967;17:554—567.